ID: h-4682ee7fdf
Hypothesis
Parthenolide changes ADORA2A coupling efficiency through membrane microdomain remodeling
The scaffold alters receptor signaling efficacy without strong orthosteric affinity by modifying redox-sensitive lipid nanodomains.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 6 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
The scaffold alters receptor signaling efficacy without strong orthosteric affinity by modifying redox-sensitive lipid nanodomains.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Adenosine Accumulation<br/>Metabolic Stress or Hypoxia"]
B["ADORA2A Engagement<br/>Gi-coupled Anti-inflammatory Receptor"]
C["cAMP Suppression<br/>PKA Activity Reduction"]
D["Microglial Activation Threshold Raised<br/>Pro-inflammatory Mediator Release Reduced"]
E["Neuroprotection<br/>Reduced Glutamate Toxicity and Oxidative Stress"]
F["ADORA2A Blockade<br/>Pro-inflammatory Activation Restored"]
A --> B
B --> C
C --> D
D --> E
F -.->|"counteracts"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix6 supports1 contradicts
Supports
Coupling-specific assays could explain downstream selectivity without direct binding.
Supports
A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?
Supports
Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity.
Supports
Mitochondrial complex I as a therapeutic target for Alzheimer's disease.
Supports
Targeting the adenosine A(2A) receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson's disease.
Supports
Caffeine for Prevention of Alzheimer's Disease: Is the A(2A) Adenosine Receptor Its Target?
Contradicts
This mechanism is currently underconstrained and easy to overfit post hoc.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ADORA2A
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for ADORA2A from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ADORA2A.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↗
Rising
7d Momentum
▲ 1.2%
Volatility
Medium
0.0347
Events (7d)
3
Price History
▼2.1%💾 Resource Usage
LLM Tokens
1,598
$0.0048
Total Cost
$0.0048
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF lipid raft integrity is pharmacologically disrupted with methyl-β-cyclodextrin (MβCD, 5 mM for 30 min) prior to parthenolide treatment, THEN the parthenolide-induced change in ADORA2A coupling effi | MβCD pretreatment attenuates parthenolide's effect on ADORA2A coupling by >50% | — no observation — | pending | 0.28 |
| IF striatal neurons or striatum-derived cell lines are treated with parthenolide (1–10 μM for 30–60 min), THEN ADORA2A G-protein coupling efficiency will change by >25% compared to vehicle control as | Significant shift in ADORA2A coupling efficiency (>25% change in either direction) | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF striatal neurons or striatum-derived cell lines are treated with parthenolide (1–10 μM for 30–60 min), THEN ADORA2A G-protein coupling efficiency will change by >25% compared to vehicle control as measured by BRET-based Gαs recruitment or GTPγS binding assay.
Predicted outcome: Significant shift in ADORA2A coupling efficiency (>25% change in either direction)
Falsification: ADORA2A G-protein coupling remains within ±15% of baseline despite parthenolide treatment, indicating no measurable effect on receptor coupling
pendingconf 28%
IF lipid raft integrity is pharmacologically disrupted with methyl-β-cyclodextrin (MβCD, 5 mM for 30 min) prior to parthenolide treatment, THEN the parthenolide-induced change in ADORA2A coupling efficiency will be abolished or reduced by >50% compared to parthenolide alone.
Predicted outcome: MβCD pretreatment attenuates parthenolide's effect on ADORA2A coupling by >50%
Falsification: MβCD pretreatment does not significantly alter the magnitude or direction of parthenolide's effect on ADORA2A coupling, suggesting membrane microdomains are not the primary mechanism
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.